Telix Pharmaceuticals (TLX) Shares Outstanding (Weighted Average) (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $480.0 million in Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $480.0 million, up 119.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $480.0 million (up 119.27% YoY), and the FY2025 annual result was $480.0 million, up 15.93% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $480.0 million in Q4 2025 per TLX's latest filing, from $218.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $480.0 million in Q4 2025 and troughed at $210.7 million in Q4 2023.
• A 3-year average of $303.2 million and a median of $218.9 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) grew 3.87% in 2024, then soared 119.27% in 2025.
• A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $210.7 million in 2023, then grew by 3.87% to $218.9 million in 2024, then soared by 119.27% to $480.0 million in 2025.
• Business Quant data shows TLX's Shares Outstanding (Weighted Average) at $480.0 million in Q4 2025, $218.9 million in Q4 2024, and $210.7 million in Q4 2023.